Jeffrey M LeidenFiled
- VRTXVERTEX PHARMACEUTICALS INC / MAExecutive Chairmanfiled Feb 26, 2026
Monthly open-market value · 24 months Filed
- Bought (open market)
- Sold (open market)
Unusual activity Estimated
- 27Exec salePublic Dec 5, 2025 · traded Dec 3, 2025
VRTX Chair Jeffrey M Leiden sold $7.1M (10b5-1 plan)
Details
- Insider
- Jeffrey M Leiden
- Company
- VERTEX PHARMACEUTICALS INC / MA
- Ticker
- VRTX
- Tx kind
- open_market_sale
- Traded
- Dec 3, 2025
- Shares
- 15,681
- Price
- $452
- Value
- $7.1M
- Is 10b5 1
- Yes
- Filed
- Dec 5, 2025
- Public from
- Dec 5, 2025
- Method version
- 2026-11-03
- 32Exec salePublic Nov 17, 2025 · traded Nov 14, 2025
VRTX Chair Jeffrey M Leiden sold $14.2M (10b5-1 plan)
Details
- Insider
- Jeffrey M Leiden
- Company
- VERTEX PHARMACEUTICALS INC / MA
- Ticker
- VRTX
- Tx kind
- open_market_sale
- Traded
- Nov 14, 2025
- Shares
- 32,234
- Price
- $440
- Value
- $14.2M
- Is 10b5 1
- Yes
- Filed
- Nov 17, 2025
- Public from
- Nov 17, 2025
- Method version
- 2026-11-03
- 29Exec salePublic Nov 17, 2025 · traded Nov 14, 2025
VRTX Chair Jeffrey M Leiden sold $9.4M (10b5-1 plan)
Details
- Insider
- Jeffrey M Leiden
- Company
- VERTEX PHARMACEUTICALS INC / MA
- Ticker
- VRTX
- Tx kind
- open_market_sale
- Traded
- Nov 14, 2025
- Shares
- 21,330
- Price
- $441
- Value
- $9.4M
- Is 10b5 1
- Yes
- Filed
- Nov 17, 2025
- Public from
- Nov 17, 2025
- Method version
- 2026-11-03
- 28Exec salePublic Nov 17, 2025 · traded Nov 13, 2025
VRTX Chair Jeffrey M Leiden sold $8.2M (10b5-1 plan)
Details
- Insider
- Jeffrey M Leiden
- Company
- VERTEX PHARMACEUTICALS INC / MA
- Ticker
- VRTX
- Tx kind
- open_market_sale
- Traded
- Nov 13, 2025
- Shares
- 18,528
- Price
- $440
- Value
- $8.2M
- Is 10b5 1
- Yes
- Filed
- Nov 17, 2025
- Public from
- Nov 17, 2025
- Method version
- 2026-11-03
Transactions
Independent third-party platform; not affiliated with or endorsed by any member of Congress. Data sourced from publicly available filings and records. Portfolio, holdings, returns, and allocations are estimates and may differ from actual values. Informational and educational only; not investment advice. Shares, prices and post-transaction holdings are exactly as reported on SEC Form 4; the whale score is a model ranking of that filed activity.